期刊文献+

磁共振测量帕金森病患者基底节区、黑质体积的研究 被引量:4

Magnetic Resonance Imaging Based Volumetry of the Basal Ganglia and Substantia Nigra in Patients with Parkinson's Disease
原文传递
导出
摘要 目的:探讨MR体积测量技术评价帕金森病(Parkinson’sdiseasePD)患者基底节区(尾状核,壳核,苍白球)、黑质体积改变的价值。方法:采用3·0TMR测量早、晚期PD患者和年龄匹配正常人对照组全脑体积、尾状核、壳核、苍白球、黑质体积。对患者进行PD统一评分量表(UPDRS)第Ⅱ、Ⅲ、Ⅴ部分评分。评分结果与患者基底节区、黑质体积行相关性分析。结果:早、晚期PD患者壳核体积较正常人分别下降12·5%(P=0·004)和26·5%(P<0·001),晚期患者较早期患者下降16·0%(P=0·002)。晚期患者苍白球体积较正常人下降19·2%(P=0·023)。PD患者壳核体积与Hoehn&Yahr分级呈负相关(r=-0·741,P<0·001)。结论:MR体积测量技术是评价PD患者基底节区、黑质体积改变的一种可靠的方法,能为PD辅助诊断提供有效的影像学指标。 Aim:To explore the value of MRI based volumetry in estimating the volumes of the caudate, putamen, globus pallidus, substantia nigra of Parkinson' s disease (PD) patients. Methods: The volumetric measurements of the total brain volume, caudate, putamen, globus pallidus, substantia nigra in PD patients and the controls were performed on a 3.0T MR scanner. The patients underwent the assessment of the sub scale Ⅱ、Ⅲ、 and Ⅴ of the Unified Parkinson's Disease Rating Scale(UPDRS) .Correlation analysis was made between the volumetric measurements and UPDRS assessment.Results: Compared to controls, the early stage PD patients and late stage PD patients had smaller volume of the putamen which decreased respectively 12.5% (P =0.004) and 26.5% (P 〈 0.001 ). The late stage PD patients had even smaller volume of the putamen 16% ( P = 0.002) than the early stage ones. The volume of the globus palldus in the late stage PD patients decreased 19.2 % ( P = 0.023 ), compared to controls. The volume of the putamen of PD patients was negatively correlated with the H&Y range( r = -0.741, P 〈 0.001 ). Conclusion:The MRI based volumetry is a reliable method in the assessment of the morphological changes of the basal ganglia and substantia nigra in PD patients. This method provides an imaging predictive marker in the diagnosis of PD.
出处 《中国临床神经科学》 2005年第3期273-278,共6页 Chinese Journal of Clinical Neurosciences
关键词 帕金森病 磁共振成像 黑质 基底节 Parkinson' s disease(PD) magnetic resonance imaging(MRI) substantia nigra basal ganglia
  • 相关文献

参考文献13

  • 1Fearnley JM,Lees AJ. Ageing and Parkinson's disease:substantia nigra regional selectivity[J]. Brain,1991,114:2283-2301 被引量:1
  • 2刘道宽等主编..锥体外系疾病[M].上海:上海科学技术出版社,2000:370.
  • 3Lucerna S. In vivo atlas of decp brain structures:with 3D reconstructions[M]. Berlin:Springer,2002 被引量:1
  • 4O'Neill J,Schuff N,Marks WJ,et al.Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease[J].Mov Dis,2002,17:917-927 被引量:1
  • 5Lisanby SH,McDonald WM. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging[J].J Neural Transm,1993,40:13-21 被引量:1
  • 6Kempster PA,Gibb WRG,Stern GM,et al. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations[J]. J Neurol Neurosurg Psychiatry,1989,52:72-76 被引量:1
  • 7Ma SY,Juha O MR,Rinne JO,et al. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts[J]. J Neurol Sci,1997,151:83-87 被引量:1
  • 8Crutcher MD,DeLong MR. Single cell studies in the primate putamen.In:Functional organization[J].Exp Brain Res ,1984,53:233-243 被引量:1
  • 9Schulz JB,Skalej M,Wedekind D,et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy[J].Ann Neurol ,1999,45:65-74 被引量:1
  • 10Ghaemi M,Hilker R,Rudolf J,et al. Differentiating multiple system atropy from Parkinson's disease:contribution of strial and midbrain MRI volumetry and multi-tracer PET imaging[J].J Neurol Neurosurg Psychiatry,2002,73:511-523 被引量:1

二级参考文献12

  • 1Kempster PA, Gibb WR, Stem GM, et al. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related mootor fluctuations. J Neurol Neurosurg Psychiatry, 1989, 52:72-76. 被引量:1
  • 2Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm, 2000, 60 Suppl: 125-137. 被引量:1
  • 3Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol, 2003, 53: S110-S118. 被引量:1
  • 4Nurmi E, Raottinen H, Kaasinen V, et al. Progression in Parkinson's disease: a positron emission tomography study with a doparaine transporter ligand ^18F-CFT. Ann Neurol, 2000, 47: 804-808. 被引量:1
  • 5Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol, 2002, 59: 580-586. 被引量:1
  • 6Fowler JS, Volkow ND, Wang GJ, et al. ^11C-cocaine: PET studies of cocaine pharmcokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol, 2001, 28: 561-572. 被引量:1
  • 7Ma Y, Dhawan V, Mentis M, et al. Parametric mapping of ^18F-FPCIT binding in early stage Parkinson' s disesse: a PET study. Synapse,2002, 45: 125-133. 被引量:1
  • 8Rinne JO, Ruottinen H, Bergman J, et al. Usefulness of a dopamine transporter PET ligand ^18F-beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry, 1999, 67: 737-741. 被引量:1
  • 9Lee C,Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol, 2000, 47: 493-503. 被引量:1
  • 10Ouchi Y, Kanno T, Okada H, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and meaocortical systems in early Parkinson' s disease: a double-tracer positron emission tomography study. Ann Neurol, 1999, 46:723-731. 被引量:1

共引文献23

同被引文献44

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部